EORTC QLQ-LC13: Quality of Life in Lung Cancer
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire—Lung Cancer Module · Also known as: QLQ-LC13
The EORTC QLQ-LC13 is a 13-item lung-cancer-specific module designed to complement the 30-item EORTC QLQ-C30 core questionnaire. Developed and validated by Bergman et al. in 1994, it measures lung-specific symptoms (dyspnea, cough, hemoptysis, chest pain) and treatment toxicities (sore mouth, dysphagia). It is the standard lung cancer-specific QoL instrument in European and international trials.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
EORTC QLQ-LC13 is indicated for patients with lung cancer (NSCLC, SCLC) at any stage undergoing surgery, chemotherapy, radiation, targeted therapy, or palliative care. Primary use is clinical trials assessing treatment efficacy and patient-reported lung-specific symptoms; secondary use in oncology clinic monitoring of symptom burden. Particularly valuable in trials where dyspnea, cough, or chest pain are primary concerns (e.g., palliative chemotherapy, best supportive care, symptom management studies).
Strengths & limitations
- Detailed lung-specific symptom assessment (dyspnea, cough, hemoptysis, chest pain, sore mouth) directly relevant to lung cancer patient experience.
- Validated in large lung cancer populations (NSCLC, SCLC, all stages) across treatment modalities (surgery, chemotherapy, radiation, palliative care).
- Brief module format (13 items) adds minimal respondent burden to QLQ-C30 core.
- Symptom scales are sensitive to treatment-related changes in respiratory function and toxicity.
- Translated into 70+ languages; international standard in lung cancer research, particularly in Europe.
- Most symptom scales contain only 1–3 items; limited granularity for assessing symptom nuance (e.g., dyspnea severity grades, dyspnea at rest vs. exertion).
- Hemoptysis and chest pain are single-item scales; lack detail for comprehensive pain assessment or hemoptysis characterization.
- Does not directly measure dyspnea severity or functional limitations from dyspnea (e.g., distance patient can walk); more a symptom presence scale than functional capacity scale.
- Limited validation in rare lung cancer subtypes (large cell carcinoma) or metastatic sites (brain metastases, bone metastases with specific symptom profiles).
Frequently asked
How does EORTC QLQ-LC13 compare to FACT-Lung?
EORTC QLQ-LC13 (13 items added to QLQ-C30) is symptom-focused with dedicated dyspnea, cough, hemoptysis scales. FACT-Lung (7-item lung subscale added to FACT-G) is broader, including functional and emotional items alongside symptoms. QLQ-LC13 is more prevalent in Europe/internationally; FACT-Lung more common in North America. Both are valid; QLQ-LC13 may be superior for symptom-specific trials, FACT-Lung for comprehensive QoL assessment.
What is the MCID for QLQ-LC13 symptom scales?
MCID for QLQ-LC13 scales is approximately 10–15 points on 0–100 scale. However, for dyspnea, even smaller changes (5–10 points) may be clinically meaningful in palliative settings where symptom relief is paramount. In trials, MCID helps contextualize statistical significance with clinical importance.
Can QLQ-LC13 distinguish dyspnea severity (mild, moderate, severe)?
QLQ-LC13 dyspnea scale (3 items) does not directly grade severity into categories. It yields a continuous 0–100 score reflecting dyspnea burden. For precise dyspnea severity grading, supplement with disease-specific dyspnea scales (Modified Borg Dyspnea Scale, mMRC dyspnea grade) that classify severity into ordinal categories.
Is QLQ-LC13 appropriate for SCLC patients?
Yes. QLQ-LC13 was validated in both NSCLC and SCLC populations. However, SCLC-specific symptom profiles (e.g., symptoms from brain metastases) may not be fully captured by the generic LC13 items. Consider SCLC-specific supplementary questions or qualitative assessment for comprehensive symptom evaluation.
How are missing data handled in QLQ-LC13 scoring?
EORTC scoring guidelines: if ≥50% of items in a scale are missing, do not score that scale. If <50% are missing, impute the mean of completed items. Single-item scales (hemoptysis, chest pain) cannot be imputed; if missing, they are not scored. Report data completeness.
Is QLQ-LC13 freely available?
QLQ instruments are copyrighted by EORTC but available for non-commercial research use (registration required via qlg.eortc.be). Validated translations in 70+ languages are available through official channels. Use licensed versions to ensure psychometric validity.
Sources
- Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer, 30A(5), 635–642. DOI: 10.1016/0959-8049(94)90535-5 ↗
- Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 85(5), 365–376. DOI: 10.1093/jnci/85.5.365 ↗
How to cite this page
ScholarGate. (2026, June 3). European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire—Lung Cancer Module. ScholarGate. https://scholargate.app/en/oncology/eortc-qlq-lc13
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Cancer Worry ScaleOncology↔ compare
- EORTC QLQ-BR23Oncology↔ compare
- EORTC QLQ-C15-PALOncology↔ compare
- EORTC QLQ-CX24Oncology↔ compare
- FACT-LungOncology↔ compare